Chargement en cours...
Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing–Remitting Multiple Sclerosis Patients
AIMS: Fingolimod, oral treatment for relapsing–remitting multiple sclerosis (RRMS), is an agonist of sphingosine and its metabolite S1P that binds their receptors, blocking the egress of lymphocytes from lymph nodes. The aim of this study was immunomonitoring of minor peripheral lymphocyte subpopula...
Enregistré dans:
| Publié dans: | CNS Neurosci Ther |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6492868/ https://ncbi.nlm.nih.gov/pubmed/27080413 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cns.12548 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|